CHEMOPREVENTION OF GASTRIC DYSPLASIA

该项目通过以下方式解决胃癌的化学预防问题 阻断慢性萎缩性胃炎和肠炎的进展 化生，胃粘膜的一种病变，可识别患者 风险很高。它代表了在中国人口中研究的继续。 哥伦比亚纳里诺，在那里对1788名受试者进行了跟踪调查 超过5年。慢性萎缩性胃炎380例及慢性萎缩性胃炎740例 胃粘膜肠化生将进入一种 测试抗氧化剂作用的随机双盲临床试验 (抗坏血酸和β-胡萝卜素)以及抗幽门螺杆菌 治疗(次水杨酸铋和呋喃唑酮)。14C尿素呼气试验 将用于监控惠普。旧病复发。阶乘设计将是 被利用了。这些药物的效果将通过以下几个方面进行评估 中间终点：癌症先兆的组织学(小肠 化生、结肠化生和异型增生)，粘液组织化学， 核仁组成区(AgNOR)与复制区的形态 用PCN-Cyclin单抗进行评价。进展和 每个参数的回归率将在不同干预措施之间进行比较 以及安慰剂组。

This project addresses the issue of chemoprevention of gastric cancer by blocking the progression of chronic atrophic gastritis and intestinal metaplasia, a lesion of the gastric mucosa which identifies patients at high risk. It represents the continuation of studies in the population of Narino, Colombia, where a cohort of 1788 subjects has been followed for over 5 years. 380 patients with chronic atrophic gastritis and 740 with intestinal metaplasia of the gastric mucosa will be entered into a randomized double blind clinical trial testing the role of antioxidants (ascorbic acid and beta-carotene) as well as anti-Helicobacter pylori therapy (bismuth sub-salicylate and furazolidone). 14C urea breath test will be used to monitor H.p. relapses. A factorial design will be utilized. The effects of the agents will be evaluated with the following intermediate end-points: histology of cancer precursors (small intestinal metaplasia, colonic metaplasia and dysplasia), mucin histochemistry, nucleolar organizer regions (AgNO3-NORs) and morphology of replication zone evaluated with PCN-cyclin monoclonal antibodies. Progression and regression rates for each parameter will be compared between intervention and placebo groups.